Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.
Vascular endothelial growth factor (VEGF) plays an important role in the pathophysiology of several sight-threatening retinal disorders such as age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy. The discovery of anti-VEGF agents has revolutionized our tr...
| Main Author: | |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2012
|
| _version_ | 1797088997719146496 |
|---|---|
| author | Chong, V |
| author_facet | Chong, V |
| author_sort | Chong, V |
| collection | OXFORD |
| description | Vascular endothelial growth factor (VEGF) plays an important role in the pathophysiology of several sight-threatening retinal disorders such as age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy. The discovery of anti-VEGF agents has revolutionized our treatment of these conditions. There are 4 anti-VEGF agents that are either approved or in common use in ophthalmology, namely pegaptanib (Macugen, Pfizer), ranibizumab (Lucentis, Novartis), aflibercept or VEGF Trap-Eye (EYLEA, Bayer) and bevacizumab (Avastin, Roche). There are differences between them. In this review, the differences are discussed in detail. Furthermore, an attempt is made to explain some of the clinical trial data based on their differences in ocular efficacy, duration of action, and local and systemic safety concerns. |
| first_indexed | 2024-03-07T02:58:08Z |
| format | Journal article |
| id | oxford-uuid:b00439ff-2922-4436-b642-fcdd65032d80 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:58:08Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:b00439ff-2922-4436-b642-fcdd65032d802022-03-27T03:53:27ZBiological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b00439ff-2922-4436-b642-fcdd65032d80EnglishSymplectic Elements at Oxford2012Chong, VVascular endothelial growth factor (VEGF) plays an important role in the pathophysiology of several sight-threatening retinal disorders such as age-related macular degeneration, diabetic macular edema and proliferative diabetic retinopathy. The discovery of anti-VEGF agents has revolutionized our treatment of these conditions. There are 4 anti-VEGF agents that are either approved or in common use in ophthalmology, namely pegaptanib (Macugen, Pfizer), ranibizumab (Lucentis, Novartis), aflibercept or VEGF Trap-Eye (EYLEA, Bayer) and bevacizumab (Avastin, Roche). There are differences between them. In this review, the differences are discussed in detail. Furthermore, an attempt is made to explain some of the clinical trial data based on their differences in ocular efficacy, duration of action, and local and systemic safety concerns. |
| spellingShingle | Chong, V Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. |
| title | Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. |
| title_full | Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. |
| title_fullStr | Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. |
| title_full_unstemmed | Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. |
| title_short | Biological, preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors. |
| title_sort | biological preclinical and clinical characteristics of inhibitors of vascular endothelial growth factors |
| work_keys_str_mv | AT chongv biologicalpreclinicalandclinicalcharacteristicsofinhibitorsofvascularendothelialgrowthfactors |